HKS Authors

See citation below for complete author information.


The Affordable Care Act phases out the Medicare Part D coverage gap over the next decade; however, beneficiaries will continue to face substantial cost-sharing even after 2020. Higher cost-sharing has been associated with reductions in necessary drug use. Non-adherence to antipsychotics, a mainstay of schizophrenia treatment, is associated with worse clinical outcomes. We investigated the impact of Part D cost-sharing on antipsychotic spending and adherence for beneficiaries with schizophrenia, focusing on within-person cost-sharing increases associated with the gap.


Fung, Vicki, Mary Price, Alisa Busch, Bruce Fireman, Rita Hui, Mary Beth Landrum, Richard G. Frank, Joseph P. Newhouse, and John Hsu. "Medicare Part D Cost Sharing and Antipsychotic Use in Two Medicare Advantage Plans." Clinical Medicine and Research 10.3 (August 2012): 182.